openPR Logo
Press release

Nonalcoholic Fatty Liver Disease (NAFLD) Market: Future Industry Scope, Growth Opportunities, and Forecast Through 2024-2031 | Pfizer Inc., AstraZeneca, Novartis AG, Takeda Pharmaceutical Company Limited., Intercept Pharmaceuticals, Inc

11-18-2024 06:52 AM CET | Health & Medicine

Press release from: DataM Intelligence 4 Market Research LLP

Nonalcoholic Fatty Liver Disease (NAFLD) Market || 2024-2031

Nonalcoholic Fatty Liver Disease (NAFLD) Market || 2024-2031

The Nonalcoholic Fatty Liver Disease (NAFLD) Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach.

Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/nonalcoholic-fatty-liver-disease-market

What is the projected growth rate (CAGR) of the Global Nonalcoholic Fatty Liver Disease (NAFLD) market from 2024 to 2031, and what is the market value expected to change by 2031?

The Global Nonalcoholic Fatty Liver Disease (NAFLD) Market is expected to reach at a high CAGR during the forecast period 2024-2031.

Nonalcoholic Fatty Liver Disease (NAFLD) is a condition where excess fat accumulates in the liver in individuals who do not consume significant amounts of alcohol. It is commonly associated with obesity, type 2 diabetes, and metabolic syndrome. NAFLD can range from simple fatty liver (steatosis) to more severe stages, such as nonalcoholic steatohepatitis (NASH), which can lead to liver scarring, cirrhosis, or even liver failure. Early diagnosis and management through lifestyle changes, such as diet and exercise, are key to preventing progression.

Key Developments:

❁ In April 2022, Oramed Pharmaceuticals Inc. acquired the patent titled "Methods and Compositions for Treating NAFLD, Hepatic Steatosis, and Sequelae Thereof" from the European Patent Office. The company has developed an oral protein delivery platform that protects therapeutic proteins from degradation in the digestive system.

❁ In March 2023, Akero Therapeutics, Inc., a clinical-stage company focused on developing transformative therapies for patients with serious metabolic disorders and significant unmet needs, announced a positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The company also shared details on the upcoming SYNCHRONY Phase 3 study schedule for efruxifermin, aimed at treating nonalcoholic steatohepatitis (NASH).

List of the Key Players in the Nonalcoholic Fatty Liver Disease (NAFLD) Market:

Pfizer Inc., AstraZeneca, Novartis AG, Takeda Pharmaceutical Company Limited., Intercept Pharmaceuticals, Inc., F. Hoffmann-La Roche Ag, Merck & Co., Inc., Abbvie Inc., And Gilead Sciences, Inc.

Research Process:

Both primary and secondary data sources have been used in the global Nonalcoholic Fatty Liver Disease (NAFLD) Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Segment Covered in the Nonalcoholic Fatty Liver Disease (NAFLD) Market:

By Drug Class: Antioxidants, Lipid-Lowering Drugs, Insulin sensitizers, Pentoxifylline, Angiotensin Receptor Blockers, Others

By Disease Stage: Non-Alcoholic Steatohepatitis (NASH), Cirrhosis, Fibrosis

By Route of Administration: Injectable, Oral, Other

By Distribution Channel: Hospital Pharmaci

Regional Breakout:

The global Nonalcoholic Fatty Liver Disease (NAFLD) Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

✫ North America (U.S., Canada, Mexico)

✫ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

✫ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

✫ South America (Colombia, Brazil, Argentina, Rest of South America)

✫ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Get Year End Discounts on Premium Report:- https://www.datamintelligence.com/buy-now-page?report=nonalcoholic-fatty-liver-disease-market

This Report Unveils:

✔ Go to Market Strategy- A roadmap to successfully product launch or service in the target market.

✔ Gain a clear picture of the market's health and growth trajectory through neutral analysis.

✔ Deep Market Insights delve into development trends, competitor landscape, supply and demand dynamics, brand share & pricing analysis year-over-year growth patterns, and key players' performance.

✔ Upon request, we can provide customized reports focusing on specific regions or countries, offering a granular view of their markets.

✔ Identify high-potential niche segments and regions poised for significant expansion.

✔ Analysis of Market Size (historical and forecast) Total Addressable Market (TAM), Serviceable Available Market (SAM), and Serviceable Obtainable Market (SOM) to understand the market's overall size and your achievable market share.

✔ Gain a comprehensive understanding of the competitive landscape, including market share distribution, key players (innovators, startups, laggards, and pioneers), and their respective strengths and weaknesses.

**The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted**

Chapter Outline:

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: key insights, key emerging trends, etc.

Chapter 3: Manufacturers competitive analysis, detailed analysis of Nonalcoholic Fatty Liver Disease (NAFLD) manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 5 & 6: Revenue of Nonalcoholic Fatty Liver Disease (NAFLD) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the Nonalcoholic Fatty Liver Disease (NAFLD) market in different market segments.

Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the Nonalcoholic Fatty Liver Disease (NAFLD) market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: The main points and conclusions of the report.

Get Customization in the report as per your requirements:- https://datamintelligence.com/customize/nonalcoholic-fatty-liver-disease-market

Frequently Asked Questions

☞ What is the expected growth rate of the global Nonalcoholic Fatty Liver Disease (NAFLD) market for the forecast period?

☞ What are the key driving factors that are responsible to shape the fate of the Nonalcoholic Fatty Liver Disease (NAFLD) market during the forecast period?

☞ What will be the overall size of the market during the analysis period?

☞ What are the prominent market trends which influence the development of the Nonalcoholic Fatty Liver Disease (NAFLD) market across various regions?

☞ Who are the key market players and the market strategies that have helped them to secure the leading position in the global market?

☞ What are the challenges and threats that are likely to act as a barrier to the growth of the Nonalcoholic Fatty Liver Disease (NAFLD) market?

☞ What are the major opportunities that the companies can get to attain success in the world?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Nonalcoholic Fatty Liver Disease (NAFLD) Market: Future Industry Scope, Growth Opportunities, and Forecast Through 2024-2031 | Pfizer Inc., AstraZeneca, Novartis AG, Takeda Pharmaceutical Company Limited., Intercept Pharmaceuticals, Inc here

News-ID: 3739864 • Views:

More Releases from DataM Intelligence 4 Market Research LLP

United States Automatic Packaging Robot Market 2025 | Industry Developments, Future Growth, Share & Industry Insights
United States Automatic Packaging Robot Market 2025 | Industry Developments, Fut …
Automatic Packaging Robot Market reached US$ 4.0 billion in 2023 and is projected to reach US$ 10.2 billion by 2031, growing at a CAGR of 12.4% during the forecast period 2024-2031. DataM Intelligence unveils its latest report on the "Automatic Packaging Robot Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and
Human Augmentation Market 2025 | Industry Developments, Future Growth, Share & Industry Insights
Human Augmentation Market 2025 | Industry Developments, Future Growth, Share & I …
The Human Augmentation Market reached US$ 252.6 billion in 2023 and is projected to reach US$ 780.7 billion by 2031, growing at a CAGR of 15.6% during the forecast period 2024-2031. DataM Intelligence unveils its latest report on the "Human Augmentation Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging
Learning Management System (LMS) Market 2025 | Industry Developments, Future Growth, Share & Industry Insights
Learning Management System (LMS) Market 2025 | Industry Developments, Future Gro …
Learning Management System (LMS) Market reached US$ 18.7 billion in 2023 and is projected to reach US$ 67.2 billion by 2031, growing at a CAGR of 17.7% during the forecast period 2024-2031. DataM Intelligence unveils its latest report on the "Learning Management System Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts,
Team Collaboration Tools Market 2025 | Industry Developments, Future Growth, Share & Industry Insights
Team Collaboration Tools Market 2025 | Industry Developments, Future Growth, Sha …
The Team Collaboration Tools Market reached US$ 23.3 billion in 2023 and is projected to reach US$ 62.8 billion by 2031, growing at a CAGR of 13.5% during the forecast period 2024-2031. DataM Intelligence unveils its latest report on the "Team Collaboration Tools Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts,

All 5 Releases


More Releases for NAFLD

Nonalcoholic Fatty Liver Disease (NAFLD) Patient Pool to Reach 1.7 Billion by 20 …
Nonalcoholic fatty liver disease (NAFLD) has emerged as one of the most pressing global health challenges of the 21st century. Characterized by the accumulation of fat in the liver not caused by alcohol consumption, NAFLD is closely associated with obesity, type 2 diabetes, and metabolic syndrome. In its severe form, nonalcoholic steatohepatitis (NASH), the disease can progress to cirrhosis, liver failure, or hepatocellular carcinoma, making it a major cause of
Non-Alcoholic Fatty Liver Disease (NAFLD) Market Detailed Industry Report Analys …
Introduction Non-Alcoholic Fatty Liver Disease (NAFLD) has emerged as one of the most pressing global health challenges of the 21st century. Closely linked to the growing prevalence of obesity, type 2 diabetes, and metabolic syndrome, NAFLD is now the most common liver disorder worldwide. It ranges from simple fat accumulation in the liver (steatosis) to the more severe inflammatory stage known as Non-Alcoholic Steatohepatitis (NASH), which can progress to fibrosis, cirrhosis,
Non-Alcoholic Fatty Liver Disease (NAFLD) Market to Rise at 5.98% CAGR, Reaching …
BREAKING: The Non-Alcoholic Fatty Liver Disease NAFLD market is positioned to become the #1 game-changing force in the global Healthcare sector by 2035, creating unprecedented growth opportunities for manufacturers, technology providers, enterprise clients, solution developers and strategic investors worldwide. This exclusive deep-dive report delivers comprehensive analysis of the rapidly evolving Non-Alcoholic Fatty Liver Disease NAFLD industry, uncovering breakthrough technological advancements, critical market milestones and transformative future projections. It explores the revolutionary
Non Alcoholic Fatty Liver Disease (NAFLD) Market to Witness Growth by 2032, Esti …
DelveInsight's "Non Alcoholic Fatty Liver Disease (NAFLD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Non Alcoholic Fatty Liver Disease (NAFLD), historical and forecasted epidemiology as well as the Non Alcoholic Fatty Liver Disease (NAFLD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Non Alcoholic Fatty Liver Disease (NAFLD) market report provides current treatment practices, emerging drugs,
Panthera leads the way in the UK with specialist research sites for NASH and NAF …
With access to leading hepatologists, biopsy theatres, fibroscans at specialist sites and ongoing mass screening programmes Panthera can help pharma and CROs find a treatment for this increasingly common, progressive, and life-threatening diseases. Non-Alcoholic steatohepatitis NASH and Non-Alcoholic Fatty liver Disease NAFLD have no approved medical treatments to treat these inflammatory conditions. Panthera is already involved with two trials with several more in the pipeline. There are over a thousand studies* underway
New Drugs for Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato …
Researchmoz added Most up-to-date research on "Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018" to its huge collection of research reports. This report provides an overview of the non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players active in this space, and also features data for dormant and discontinued